PMID- 27040186
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20211204
IS  - 1531-4332 (Electronic)
IS  - 1095-6433 (Linking)
VI  - 198
DP  - 2016 Aug
TI  - Roles of mechanistic target of rapamycin and transforming growth factor-beta 
      signaling in the molting gland (Y-organ) of the blackback land crab, Gecarcinus 
      lateralis.
PG  - 15-21
LID - S1095-6433(16)30063-0 [pii]
LID - 10.1016/j.cbpa.2016.03.018 [doi]
AB  - Molting in decapod crustaceans is controlled by molt-inhibiting hormone (MIH), an 
      eyestalk neuropeptide that suppresses production of ecdysteroids by a pair of 
      molting glands (Y-organs or YOs). Eyestalk ablation (ESA) activates the YOs, 
      which hypertrophy and increase ecdysteroid secretion. At mid premolt, which 
      occurs 7-14days post-ESA, the YO transitions to the committed state; hemolymph 
      ecdysteroid titers increase further and the animal reaches ecdysis ~3weeks 
      post-ESA. Two conserved signaling pathways, mechanistic target of rapamycin 
      (mTOR) and transforming growth factor-beta (TGF-beta), are expressed in the Gecarcinus 
      lateralis YO. Rapamycin, an mTOR antagonist, inhibits YO ecdysteroidogenesis in 
      vitro. In this study, rapamycin lowered hemolymph ecdysteroid titer in ESA G. 
      lateralis in vivo; levels were significantly lower than in control animals at all 
      intervals (1-14days post-ESA). Injection of SB431542, an activin TGF-beta receptor 
      antagonist, lowered hemolymph ecdysteroid titers 7 and 14days post-ESA, but had 
      no effect on ecdysteroid titers at 1 and 3days post-ESA. mRNA levels of mTOR 
      signaling genes Gl-mTOR, Gl-Akt, and Gl-S6k were increased by 3days post-ESA; the 
      increases in Gl-mTOR and Gl-Akt mRNA levels were blocked by SB431542. 
      Gl-elongation factor 2 and Gl-Rheb mRNA levels were not affected by ESA, but 
      SB431542 lowered mRNA levels at Days 3 and 7 post-ESA. The mRNA level of an 
      activin TGF-beta peptide, Gl-myostatin-like factor (Mstn), increased 5.5-fold from 0 
      to 3days post-ESA, followed by a 50-fold decrease from 3 to 7days post-ESA. These 
      data suggest that (1) YO activation involves an up regulation of the mTOR 
      signaling pathway; (2) mTOR is required for YO commitment; and (3) a Mstn-like 
      factor mediates the transition of the YO from the activated to the committed 
      state.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Abuhagr, Ali M
AU  - Abuhagr AM
AD  - Department of Biology, Colorado State University, Fort Collins, CO 80523, USA.
FAU - MacLea, Kyle S
AU  - MacLea KS
AD  - Department of Biology, Colorado State University, Fort Collins, CO 80523, USA.
FAU - Mudron, Megan R
AU  - Mudron MR
AD  - Department of Biology, Colorado State University, Fort Collins, CO 80523, USA.
FAU - Chang, Sharon A
AU  - Chang SA
AD  - Bodega Marine Laboratory, University of California, Davis, Bodega Bay, CA 94923, 
      USA.
FAU - Chang, Ernest S
AU  - Chang ES
AD  - Bodega Marine Laboratory, University of California, Davis, Bodega Bay, CA 94923, 
      USA.
FAU - Mykles, Donald L
AU  - Mykles DL
AD  - Department of Biology, Colorado State University, Fort Collins, CO 80523, USA. 
      Electronic address: Donald.Mykles@ColoState.edu.
LA  - eng
PT  - Journal Article
DEP - 20160331
PL  - United States
TA  - Comp Biochem Physiol A Mol Integr Physiol
JT  - Comparative biochemistry and physiology. Part A, Molecular & integrative 
      physiology
JID - 9806096
RN  - 0 (4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide)
RN  - 0 (Benzamides)
RN  - 0 (Dioxoles)
RN  - 0 (Ecdysteroids)
RN  - 0 (Transforming Growth Factor beta)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Benzamides/pharmacology
MH  - Brachyura/anatomy & histology/drug effects/*metabolism
MH  - Dioxoles/pharmacology
MH  - Ecdysteroids/metabolism
MH  - Gene Expression Regulation/drug effects
MH  - Hemolymph/drug effects/metabolism
MH  - Molting/physiology
MH  - Signal Transduction
MH  - Sirolimus/pharmacology
MH  - TOR Serine-Threonine Kinases/genetics/*metabolism
MH  - Transforming Growth Factor beta/*metabolism
OTO - NOTNLM
OT  - Activin
OT  - Akt
OT  - Crustacean
OT  - Ecdysteroid
OT  - Molting
OT  - Myostatin, Rheb
OT  - Target of rapamycin
OT  - Transforming growth factor-beta
OT  - Y-organ
OT  - p70 S6 kinase
EDAT- 2016/04/05 06:00
MHDA- 2017/06/14 06:00
CRDT- 2016/04/05 06:00
PHST- 2015/12/27 00:00 [received]
PHST- 2016/03/18 00:00 [revised]
PHST- 2016/03/23 00:00 [accepted]
PHST- 2016/04/05 06:00 [entrez]
PHST- 2016/04/05 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
AID - S1095-6433(16)30063-0 [pii]
AID - 10.1016/j.cbpa.2016.03.018 [doi]
PST - ppublish
SO  - Comp Biochem Physiol A Mol Integr Physiol. 2016 Aug;198:15-21. doi: 
      10.1016/j.cbpa.2016.03.018. Epub 2016 Mar 31.